An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
Biosense Webster EMEA, a Division of Johnson & Johnson Medical NV/SA and leader in the treatment of Atrial Fibrillation has today, during AF Association Global AF Aware Week, published a report that uncovers the growing burden of AF on patients, caregivers and healthcare systems across Europe.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
Each year, at least 3 million people worldwide die of sudden cardiac death. In the U.S., this number reaches up to 450,000 people.
Augmented reality, a technology that superimposes computer-generated information on a user's view of the real world, offers a new platform to help physicians better visualize complex medical data, particularly before and during medical procedures.
Sudden cardiac death is a common cause of death in patients with congenital or acquired heart disease. An implanted cardiac defibrillator can effectively put a stop to any underlying cardiac arrhythmia.
Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.
Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).
Checking the heartbeat of babies in the womb is set to become more accurate and less stressful for expectant mothers thanks to research by the University of Sussex.
An interview with Glyn Barnes, Marketing Director for AliveCor, about Kardia Mobile and the Kardia Band, the FDA approved devices which can provide a diagnostic quality ECG reading in 30 seconds.
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.
Atrial fibrillation is the most common type of irregular heartbeat, or cardiac arrhythmia, affecting 2-3 % of the European population and as many as one in 10 people over the age of 80.
Despite being the most common heart arrhythmia disorder in the U.S., there is not much research on the causes of atrial fibrillation in minority populations.
In a proof of concept study, scientists at Johns Hopkins report they have successfully performed 3D personalized virtual simulations of the heart to accurately identify where cardiac specialists should electrically destroy cardiac tissue to stop potentially fatal irregular and rapid heartbeats in patients with scarring in the heart.
Butterflies in a patient's stomach are one thing, but palpitations in their chest can mean serious heart problems.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
A clinical trial of more than 1,000 patients with implantable cardioverter defibrillators found that the drug ranolazine was safe but didn't significantly decrease the likelihood of the first occurrence of ventricular tachycardia, ventricular fibrillation or death in this high-risk population.
Left atrial fibrosis may explain the increased risk of arrhythmias seen in highly trained endurance athletes, according to research presented today at ESC Congress 2018.
Scientists at the Virginia Tech Carilion Research Institute have found evidence that may disrupt conventional understanding about how electrical activity travels in the heart -; a discovery that potentially can lead to new insight into medical problems such as heart arrhythmia and sudden cardiac death.
Royal Philips, a global leader in health technology, today introduced the EPIQ CVx cardiovascular ultrasound system. Built on the powerful EPIQ ultrasound platform, EPIQ CVx is specifically designed to increase diagnostic confidence and simplify workflow for clinicians, giving them more time to interact with their patients and reducing the need for repeat scans.
A toxin from the desert bush spider is helping researchers understand more about human and insect biology, which could lead to new treatments for health conditions and bee-friendly insecticides.